{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:47:39Z","timestamp":1766155659776,"version":"3.41.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":70,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada ULC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100896","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:28:02Z","timestamp":1741814882000},"page":"100896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-1808","authenticated-orcid":false,"given":"William J","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horia","family":"Marginean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alrehaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa Ahmed","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Asmis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100896_bib0001","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer","volume":"325","author":"Biller","year":"2021","journal-title":"JAMa"},{"key":"10.1016\/j.ctarc.2025.100896_bib0002","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/EDBK_349561","article-title":"The evolving treatment landscape in BRAF-V600E \u2013Mutated metastatic colorectal cancer","author":"Tabernero","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. B."},{"key":"10.1016\/j.ctarc.2025.100896_bib0003","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1634\/theoncologist.2009-0233","article-title":"Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery","volume":"15","author":"Tejpar","year":"2010","journal-title":"Oncologist."},{"key":"10.1016\/j.ctarc.2025.100896_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215369","article-title":"BRAF-mutated colorectal cancer: clinical and molecular insights","volume":"20","author":"Caputo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.100896_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2014.09.041","article-title":"Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes","volume":"148","author":"Sinicrope","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctarc.2025.100896_bib0006","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2025.100896_bib0008","first-page":"e69","article-title":"Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study","volume":"17","author":"Kayhanian","year":"2018","journal-title":"Clin. Colorectal. Cancer"},{"key":"10.1016\/j.ctarc.2025.100896_bib0009","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF -mutated advanced colorectal cancer: a rapidly changing therapeutic landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0010","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100896_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0012","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100896_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus Cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0014","doi-asserted-by":"crossref","first-page":"e13081","DOI":"10.1200\/JCO.2018.36.15_suppl.e13081","article-title":"Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): the GIM-13 AMBRA study","volume":"36","author":"Cazzaniga","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ctarc.2025.100896_bib0016","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ctarc.2025.100896_bib0017","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0018","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: results from a single-arm, phase II study of Encorafenib plus Binimetinib and Cetuximab in previously untreated BRAF V600E -mutant metastatic colorectal cancer","volume":"41","author":"Van Cutsem","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2023.41.4_suppl.119","article-title":"BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy for BRAF V600E metastatic colorectal cancer (mCRC)","volume":"41","author":"Kopetz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2025.100896_bib0021","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0022","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and Bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100896_bib0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0024","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus Bevacizumab versus doublets plus Bevacizumab as initial therapy of unresectable metastatic colorectal cancer","volume":"38","author":"Cremolini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0025","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus Cetuximab or Bevacizumab as first-line treatment of BRAF V600E -mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study","volume":"41","author":"Stintzing","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0026","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100896_bib0027","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch repair and microsatellite instability testing for Immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0028","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line Nivolumab plus low-dose Ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the Phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0030","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: optimal management review","volume":"25","author":"S\u00e1nchez-Hidalgo","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0031","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12672-021-00398-6","article-title":"Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: a systematic review and meta-analysis","volume":"12","author":"Fadel","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2025.100896_bib0032","first-page":"13","article-title":"Brain metastases from colorectal cancer: a systematic review of the literature and meta-analysis to establish a guideline for daily treatment","author":"M\u00fcller","year":"2021","journal-title":"Cancers. (Basel)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:08:04Z","timestamp":1754060884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"alternative-id":["S2468294225000346"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100896","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100896"}}